IMAAVY DIN 02563509
Status: Marketed
Holder: JANSSEN INC
Health Canada record
| Active ingredient(s) | NIPOCALIMAB 300 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Intravenous |
|---|
| Schedule | SCHEDULE D; PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L04AL03 NIPOCALIMAB |
|---|
| Original market date | 23-Jan-2026 |
|---|
| Current status date | 23-Jan-2026 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Janssen Inc — licence 100239, currently licensed, last inspection rating C (2026-03-09).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing NIPOCALIMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02563517 | IMAAVY | JANSSEN INC | Solution | NIPOCALIMAB 1200 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 36540 | 2025-12-05 | New Drug Submission (NDS) | |
Request a quote for IMAAVY
How to read a Canadian DIN record